Samsung Biologics Expands ADC Services with a Cutting-Edge Facility
Strengthened Partnership Highlights Proven Expertise and Shared Vision
Samsung Biologics, a leading global contract development and manufacturing organization (CDMO), has announced an extended partnership with LigaChem Biosciences to deliver advanced antibody-drug conjugate (ADC) services.
As part of this partnership, Samsung Biologics will provide support for several ADC programs by LigaChem Biosciences at its newly launched, state-of-the-art ADC facility. Building on the success of their previous efforts to develop treatments targeting solid tumors, LigaChem Biosciences continues to lead the way in ADC innovation with a strong focus on research and development.
“This expanded partnership underscores our commitment to offering exceptional ADC development and manufacturing solutions,” stated John Rim, CEO and President of Samsung Biologics. “Leveraging our advanced facilities and extensive expertise, we strive to deliver safe, high-quality therapies to patients while ensuring efficient and seamless execution for our collaborators.”
Yong-Zu Kim, President and CEO of LigaChem Biosciences, shared his perspective: “Partnering with Samsung Biologics is a significant step toward strengthening the supply chain for high-quality ADCs. Together, we aim to accelerate the development of innovative treatments and ensure their timely delivery to patients by leveraging Samsung Biologics’ extensive CDMO experience.”
Samsung Biologics’ newly launched ADC facility features a segregated suite equipped with a 500-liter reactor, designed to manage all stages of ADC development and manufacturing. Building on its established expertise in large-scale antibody production and process engineering, Samsung Biologics provides end-to-end ADC services, covering everything from late-stage discovery to development and conjugation.
Additionally, Samsung Biologics continues to invest in cutting-edge technologies through the Samsung Life Science Fund, supporting biotech companies advancing ADC linker technologies, protein engineering, and toolkits to foster innovation in the field.